Developer docs
API playgroundTry for free, no card

Search company profiles

Mepsgen

Full company profile

uuid0002lr8

Namestring
Mepsgen
Legal namestring
MEPSGEN Co., Ltd.
Websiteurl
mepsgen.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

MEPSGEN (MEPSGEN Co., Ltd.) is a privately held Korean biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company develops and commercializes microphysiological systems (MPS) and microfluidic nanoparticle synthesis platforms that enable pharmaceutical companies, biotechnology firms, and academic research institutions to conduct preclinical drug screening, disease modeling, and scalable nanomedicine manufacturing. Its core product lines are ProMEPS® (an automated robotic 3D MPS modeling system for high-throughput drug candidate evaluation), the MEPS-X series of microphysiological chips (covering blood-brain barrier, skin, corneal epithelial, placental, intestinal mucosal, vascular endothelial, blood-retina, and kidney tubular epithelial barrier models, plus organoid and tumor-microenvironment chips), the NanoCalibur® automated nanoparticle synthesis system (available in Mini, Lab, Pro, and GMP variants), and the MST-X microvortex system for scalable lipid nanoparticle production. The company also operates the MG-X nanomedicine pipeline, including MG-PE3 and MG-Sh19 for Alzheimer's disease and MG-GHC24 for glioblastoma.

MEPSGEN generates revenue through three channels: hardware sales of MPS and nanoparticle synthesis instruments, research services leveraging its own platforms for drug screening and disease mechanism studies, and licensing/co-development agreements with strategic partners. Pricing is quote-based with custom enterprise contracts. Go-to-market is event-driven and sales-led: the company exhibits at BIO USA, BIO KOREA, BIO Japan, MPS World Summit, and BIX- BIOPLUS INTERPHEX KOREA, and runs a direct enterprise field-sales motion targeting pharmaceutical and large biotech accounts. Strategic partnerships anchor the technology base, including an exclusive technology transfer agreement with Georgia Tech (commercialized via US subsidiary Mepsgenlab Inc.), co-development with Imperial College London on intestinal/IBD models, and a glioblastoma tumor-microenvironment collaboration with Sungkyunkwan University. The company is recognized as a 2026 Global IP Star Company by the Korean Intellectual Property Office (KIPO) and received the Presidential Citation at the 2025 Venture Entrepreneurship Awards.

Short descriptiontext

MEPSGEN is a Korean biotechnology company that develops microphysiological systems (MPS) and microfluidic nanoparticle synthesis platforms — including ProMEPS®, MEPS-X chips, NanoCalibur®, and MST-X — serving pharmaceutical companies, biotech firms, and academic research institutions with drug screening, disease modeling, and scalable nanoparticle drug delivery applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microphysiological systems, organ-on-chip platforms, nanoparticle synthesis systems, drug discovery tools, nanomedicine delivery
Industry4 codes
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAHALAJ
MEMS Actuators & Micro-Mechanisms (Micromirrors/Microfluidics)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Microphysiological Systems
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Research Equipment Sales
TypeHardware Sales
Description

Sale of proprietary MPS platforms (ProMEPS®, MEPS-X) and nanoparticle synthesis systems (NanoCalibur®, MST-X) to pharmaceutical companies, biotech firms, and research institutions for drug discovery and development.

mepsgen.com
2Research Services
TypeProfessional Services
Description

Providing research services using company's MPS platforms and technology for drug screening, disease mechanism studies, and early diagnosis applications.

mepsgen.com
3Licensing and Co-development
TypeLicensing Royalties
Description

Revenue from strategic partnerships including co-development agreements with pharmaceutical companies for drug delivery technologies and model development, as evidenced by partnerships with Imperial College London and HLB Pharmaceutical.

mepsgen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise equipment pricing - custom quotes
ModelOtherBilling cadenceMulti-year contract
Notes

Custom pricing based on configuration, volume, and specific customer requirements for MPS platforms and nanoparticle synthesis systems.

mepsgen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1ProMEPS®
Description

Automated 3D Microphysiological System for High-throughput Screening of Drug Candidates

mepsgen.com
+4 more records
Core offering1 text field

MEPSGEN designs, manufactures, and sells microphysiological system (MPS) instruments and microfluidic chips (ProMEPS®, MEPS-X series) alongside automated nanoparticle synthesis systems (NanoCalibur® variants, MST-X microvortex) for pharmaceutical and biotechnology drug discovery, development, and delivery applications. The company also operates a proprietary nanomedicine pipeline (MG-X series) targeting Alzheimer's disease and glioblastoma, and provides contract research services using its platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • High-throughput cell and hydrogel injection (32 units)
+1 more record
Product overview1 text field

MEPSGEN is a biotechnology company offering an integrated platform of microphysiological systems (MPS) and nanoparticle synthesis technologies for drug development. The core product portfolio includes ProMEPS® (automated MPS modeling system), the MEPS-X series (chip-based tissue barrier and organoid platforms), NanoCalibur® (automated microfluidic nanoparticle synthesis systems from lab to GMP scale), and MST-X (microvortex system for lipid nanoparticle production). The company also operates the MG-X nanomedicine pipeline targeting Alzheimer's disease and brain tumors. These products work together to enable discovery-to-preclinical drug testing workflows using 3D human tissue models combined with scalable nanoparticle manufacturing capabilities.

Product and service6 records
1ProMEPS®
CategoryMicrophysiological Systems / Drug Discovery Instruments
Description

Automated 3D Microphysiological System (MPS) that uses robotic operation to deliver highly reproducible, high-throughput modeling and screening of drug candidates across multiple tissue barriers (brain, vasculature, liver, lung, kidney, skin), targeted at pharmaceutical, biotech, and academic drug-discovery laboratories.

2MEPS-X Series Microphysiological System Chips
CategoryMicrophysiological Systems / Microfluidic Chips
Description

Manufactured plastic microfluidic chip platform enabling organ-level tissue modeling, comprising MEPS-TBC-WL (3D Tissue Barrier Chip, Bottom Well), MEPS-ORD-WL and MEPS-ORD-WU (Organoid-on-a-Chip, Bottom and Upper Well types) and MEPS-TBC-CH (2D Tissue Barrier Chip, Bottom Channel), used by pharma, biotech, and academic researchers for disease modeling and drug screening.

3NanoCalibur® Automated Nanoparticle Synthesis System
CategoryNanoparticle Synthesis Equipment
Description

Automated microfluidic synthesis system for producing nanoparticles with precisely defined properties and tunable scalability, offered in Mini, Lab, Pro, and GMP versions, for use by pharmaceutical, biotech, and nanomedicine developers from research through clinical manufacturing.

4MST-X Microvortex System
CategoryNanoparticle Manufacturing Equipment
Description

Microvortex-based microfluidic system for the scalable, high-throughput production of highly uniform lipid nanoparticles encapsulating mRNAs and other payloads, intended for companies developing nanoparticle-based drug delivery and mRNA therapeutics.

5MG-X Nanomedicine Pipeline
CategoryNanomedicine Pipeline
Description

Proprietary nanoparticle drug-delivery pipeline including MG-PE3 and MG-Sh19 for Alzheimer's disease and MG-GHC24 for glioblastoma brain tumors, positioned as MEPSGEN's therapeutic candidates leveraging its nanoparticle delivery platform.

6Research Services
CategoryContract Research Services
Description

Contract research services performed using MEPSGEN's microphysiological systems and nanoparticle platforms, supporting drug screening, disease-mechanism studies, early diagnosis applications, and nanoparticle formulation work for pharmaceutical, biotech, and academic customers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-29
Description

Partnership to co-develop Inflammatory Bowel Disease (IBD) model using MEPSGEN's MPS platform technology. Also established partnership with Imperial College London's newly established Centre for Intestinal Systems (announced 2026.01.16) for advancing intestinal research models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Strategic partnership to strengthen competitiveness in next-generation drug delivery technologies. Combines HLB Pharmaceutical's drug development capabilities with MEPSGEN's nanoparticle synthesis and drug delivery system expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Partnership to develop glioblastoma tumor microenvironment model. Leverages university's research capabilities combined with MEPSGEN's tumor-on-a-chip technology (MEPS-TME) for advanced cancer research.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusive technology transfer agreement with Georgia Tech for Microengineered Tissue Barrier System technology. Includes both granted and pending patents. US subsidiary Mepsgenlab Inc. established for commercialization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Fluigent provides microfluidic flow-control instrumentation and nanoparticle formulation systems, comparable to MEPSGEN's microfluidic instrumentation side and serving similar academic/biopharma research customers.

TypeDirect peer
Description

InSphero provides 3D in vitro microtissue models and Akura flow organ-on-chip platforms, comparable to MEPSGEN's organoid-on-a-chip and 3D tissue barrier offerings for pharma drug screening.

TypeDirect peer
Description

TissUse develops multi-organ-chip (MOC) microphysiological systems for substance testing and disease modeling, competing with MEPSGEN in the MPS hardware and tissue-barrier-chip category.

4CN Bio
TypeDirect peer
Description

CN Bio provides single- and multi-organ MPS platforms (PhysioMimix) used for drug discovery and disease modeling, overlapping with MEPSGEN's ProMEPS® value proposition for preclinical human testing.

TypeOthers
Description

Denali is a CNS-focused biotech developing therapeutics for neurodegeneration including Alzheimer's, comparable to MEPSGEN's MG-X nanomedicine pipeline (MG-PE3 for Alzheimer's) on the therapeutic-program side rather than the instruments business.

TypeEmerging player
Description

Organovo develops 3D bioprinted human tissues for drug discovery and disease modeling, an adjacent tissue-engineering approach to MEPSGEN's organ-on-chip MPS platforms for preclinical drug testing.

TypeBroad incumbent
Description

Precision NanoSystems (now part of Cytiva) is the dominant supplier of microfluidic nanoparticle/LNP manufacturing systems (NanoAssemblr), the most established direct competitor to MEPSGEN's NanoCalibur® and MST-X microvortex systems.

8Dolomite Microfluidics
TypeDirect peer
Description

Dolomite (Blacktrace Holdings) supplies microfluidic chips and systems for nanoparticle synthesis and droplet microfluidics, overlapping with MEPSGEN's microfluidic nanoparticle production platforms across lab-scale applications.

TypeDirect peer
Description

Emulate is the leading commercial organ-on-chip company (Liver-Chip, Brain-Chip, etc.), directly competing with MEPSGEN's ProMEPS® and MEPS-X platforms in pharmaceutical preclinical testing and human-relevant disease modeling.

TypeDirect peer
Description

Mimetas sells the OrganoPlate organ-on-a-chip platform for high-throughput 3D tissue modeling, directly comparable to MEPSGEN's MEPS-X series chips and addressing the same pharma/biotech screening customer base.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mepsgen

Drug Discovery Microphysiological Systemsmepsgen.com

MEPSGEN is a Korean biotechnology company that develops microphysiological systems (MPS) and microfluidic nanoparticle synthesis platforms — including ProMEPS®, MEPS-X chips, NanoCalibur®, and MST-X — serving pharmaceutical companies, biotech firms, and academic research institutions with drug screening, disease modeling, and scalable nanoparticle drug delivery applications.

What Mepsgen does

MEPSGEN (MEPSGEN Co., Ltd.) is a privately held Korean biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company develops and commercializes microphysiological systems (MPS) and microfluidic nanoparticle synthesis platforms that enable pharmaceutical companies, biotechnology firms, and academic research institutions to conduct preclinical drug screening, disease modeling, and scalable nanomedicine manufacturing. Its core product lines are ProMEPS® (an automated robotic 3D MPS modeling system for high-throughput drug candidate evaluation), the MEPS-X series of microphysiological chips (covering blood-brain barrier, skin, corneal epithelial, placental, intestinal mucosal, vascular endothelial, blood-retina, and kidney tubular epithelial barrier models, plus organoid and tumor-microenvironment chips), the NanoCalibur® automated nanoparticle synthesis system (available in Mini, Lab, Pro, and GMP variants), and the MST-X microvortex system for scalable lipid nanoparticle production. The company also operates the MG-X nanomedicine pipeline, including MG-PE3 and MG-Sh19 for Alzheimer's disease and MG-GHC24 for glioblastoma.

MEPSGEN generates revenue through three channels: hardware sales of MPS and nanoparticle synthesis instruments, research services leveraging its own platforms for drug screening and disease mechanism studies, and licensing/co-development agreements with strategic partners. Pricing is quote-based with custom enterprise contracts. Go-to-market is event-driven and sales-led: the company exhibits at BIO USA, BIO KOREA, BIO Japan, MPS World Summit, and BIX- BIOPLUS INTERPHEX KOREA, and runs a direct enterprise field-sales motion targeting pharmaceutical and large biotech accounts. Strategic partnerships anchor the technology base, including an exclusive technology transfer agreement with Georgia Tech (commercialized via US subsidiary Mepsgenlab Inc.), co-development with Imperial College London on intestinal/IBD models, and a glioblastoma tumor-microenvironment collaboration with Sungkyunkwan University. The company is recognized as a 2026 Global IP Star Company by the Korean Intellectual Property Office (KIPO) and received the Presidential Citation at the 2025 Venture Entrepreneurship Awards.

Mepsgen firmographics

Firmographics
Name
Mepsgen
Legal name
MEPSGEN Co., Ltd.
Website
https://mepsgen.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
MEPSGEN is a Korean biotechnology company that develops microphysiological systems (MPS) and microfluidic nanoparticle synthesis platforms — including ProMEPS®, MEPS-X chips, NanoCalibur®, and MST-X — serving pharmaceutical companies, biotech firms, and academic research institutions with drug screening, disease modeling, and scalable nanoparticle drug delivery applications.
Ownership category
akta.pro rank

Mepsgen industry classification

Industry
Product category
Drug Discovery Microphysiological Systems
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAHALAJ
MEMS Actuators & Micro-Mechanisms (Micromirrors/Microfluidics)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Microphysiological systems
  • Organ-on-chip platforms
  • Nanoparticle synthesis systems
  • Drug discovery tools
  • Nanomedicine delivery

Where Mepsgen is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Mepsgen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Research Equipment Sales: Sale of proprietary MPS platforms (ProMEPS®, MEPS-X) and nanoparticle synthesis systems (NanoCalibur®, MST-X) to pharmaceutical companies, biotech firms, and research institutions for drug discovery and development.
  2. Research Services: Providing research services using company's MPS platforms and technology for drug screening, disease mechanism studies, and early diagnosis applications.
  3. Licensing and Co-development: Revenue from strategic partnerships including co-development agreements with pharmaceutical companies for drug delivery technologies and model development, as evidenced by partnerships with Imperial College London and HLB Pharmaceutical.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise equipment pricing - custom quotes

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Mepsgen product offering

Product offering

Core offering

MEPSGEN designs, manufactures, and sells microphysiological system (MPS) instruments and microfluidic chips (ProMEPS®, MEPS-X series) alongside automated nanoparticle synthesis systems (NanoCalibur® variants, MST-X microvortex) for pharmaceutical and biotechnology drug discovery, development, and delivery applications. The company also operates a proprietary nanomedicine pipeline (MG-X series) targeting Alzheimer's disease and glioblastoma, and provides contract research services using its platforms.

Product overview

MEPSGEN is a biotechnology company offering an integrated platform of microphysiological systems (MPS) and nanoparticle synthesis technologies for drug development. The core product portfolio includes ProMEPS® (automated MPS modeling system), the MEPS-X series (chip-based tissue barrier and organoid platforms), NanoCalibur® (automated microfluidic nanoparticle synthesis systems from lab to GMP scale), and MST-X (microvortex system for lipid nanoparticle production). The company also operates the MG-X nanomedicine pipeline targeting Alzheimer's disease and brain tumors. These products work together to enable discovery-to-preclinical drug testing workflows using 3D human tissue models combined with scalable nanoparticle manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • ProMEPS®: Automated 3D Microphysiological System for High-throughput Screening of Drug Candidates
  • MEPS-X
  • NanoCalibur®
  • MST-X
  • MG-X

Products and services

  • ProMEPS® Automated 3D Microphysiological System (MPS) that uses robotic operation to deliver highly reproducible, high-throughput modeling and screening of drug candidates across multiple tissue barriers (brain, vasculature, liver, lung, kidney, skin), targeted at pharmaceutical, biotech, and academic drug-discovery laboratories.
  • MEPS-X Series Microphysiological System Chips Manufactured plastic microfluidic chip platform enabling organ-level tissue modeling, comprising MEPS-TBC-WL (3D Tissue Barrier Chip, Bottom Well), MEPS-ORD-WL and MEPS-ORD-WU (Organoid-on-a-Chip, Bottom and Upper Well types) and MEPS-TBC-CH (2D Tissue Barrier Chip, Bottom Channel), used by pharma, biotech, and academic researchers for disease modeling and drug screening.
  • NanoCalibur® Automated Nanoparticle Synthesis System Automated microfluidic synthesis system for producing nanoparticles with precisely defined properties and tunable scalability, offered in Mini, Lab, Pro, and GMP versions, for use by pharmaceutical, biotech, and nanomedicine developers from research through clinical manufacturing.
  • MST-X Microvortex System Microvortex-based microfluidic system for the scalable, high-throughput production of highly uniform lipid nanoparticles encapsulating mRNAs and other payloads, intended for companies developing nanoparticle-based drug delivery and mRNA therapeutics.
  • MG-X Nanomedicine Pipeline Proprietary nanoparticle drug-delivery pipeline including MG-PE3 and MG-Sh19 for Alzheimer's disease and MG-GHC24 for glioblastoma brain tumors, positioned as MEPSGEN's therapeutic candidates leveraging its nanoparticle delivery platform.
  • Research Services Contract research services performed using MEPSGEN's microphysiological systems and nanoparticle platforms, supporting drug screening, disease-mechanism studies, early diagnosis applications, and nanoparticle formulation work for pharmaceutical, biotech, and academic customers.

Quantifiable outcome

  • High-throughput cell and hydrogel injection (32 units)
  • +1 more outcomes

Companies that use Mepsgen

Customer profile

Segments3 records

Ideal customer profiles3 records

Mepsgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Mepsgen partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Imperial College LondoncoreStrategic or Co-development Partner · 29 May 2026Partnership to co-develop Inflammatory Bowel Disease (IBD) model using MEPSGEN's MPS platform technology. Also established partnership with Imperial College London's newly established Centre for Intestinal Systems (announced 2026.01.16) for advancing intestinal research models.
  • HLB PharmaceuticalcoreStrategic or Co-development Partner · 28 April 2026Strategic partnership to strengthen competitiveness in next-generation drug delivery technologies. Combines HLB Pharmaceutical's drug development capabilities with MEPSGEN's nanoparticle synthesis and drug delivery system expertise.
  • Sungkyunkwan UniversitycoreStrategic or Co-development Partner · 4 November 2025Partnership to develop glioblastoma tumor microenvironment model. Leverages university's research capabilities combined with MEPSGEN's tumor-on-a-chip technology (MEPS-TME) for advanced cancer research.
  • Georgia Tech (Mepsgenlab Inc.)coreTechnology or IntegrationExclusive technology transfer agreement with Georgia Tech for Microengineered Tissue Barrier System technology. Includes both granted and pending patents. US subsidiary Mepsgenlab Inc. established for commercialization.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Mepsgen competitors and assessment

Company assessment

Emerging players

  • Fluigent: Fluigent provides microfluidic flow-control instrumentation and nanoparticle formulation systems, comparable to MEPSGEN's microfluidic instrumentation side and serving similar academic/biopharma research customers.
  • Organovo: Organovo develops 3D bioprinted human tissues for drug discovery and disease modeling, an adjacent tissue-engineering approach to MEPSGEN's organ-on-chip MPS platforms for preclinical drug testing.

Direct peers

  • InSphero: InSphero provides 3D in vitro microtissue models and Akura flow organ-on-chip platforms, comparable to MEPSGEN's organoid-on-a-chip and 3D tissue barrier offerings for pharma drug screening.
  • TissUse: TissUse develops multi-organ-chip (MOC) microphysiological systems for substance testing and disease modeling, competing with MEPSGEN in the MPS hardware and tissue-barrier-chip category.
  • CN Bio: CN Bio provides single- and multi-organ MPS platforms (PhysioMimix) used for drug discovery and disease modeling, overlapping with MEPSGEN's ProMEPS® value proposition for preclinical human testing.
  • Dolomite Microfluidics: Dolomite (Blacktrace Holdings) supplies microfluidic chips and systems for nanoparticle synthesis and droplet microfluidics, overlapping with MEPSGEN's microfluidic nanoparticle production platforms across lab-scale applications.
  • Emulate: Emulate is the leading commercial organ-on-chip company (Liver-Chip, Brain-Chip, etc.), directly competing with MEPSGEN's ProMEPS® and MEPS-X platforms in pharmaceutical preclinical testing and human-relevant disease modeling.
  • Mimetas: Mimetas sells the OrganoPlate organ-on-a-chip platform for high-throughput 3D tissue modeling, directly comparable to MEPSGEN's MEPS-X series chips and addressing the same pharma/biotech screening customer base.

Others

  • Denali Therapeutics: Denali is a CNS-focused biotech developing therapeutics for neurodegeneration including Alzheimer's, comparable to MEPSGEN's MG-X nanomedicine pipeline (MG-PE3 for Alzheimer's) on the therapeutic-program side rather than the instruments business.

Broad incumbents

  • Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva) is the dominant supplier of microfluidic nanoparticle/LNP manufacturing systems (NanoAssemblr), the most established direct competitor to MEPSGEN's NanoCalibur® and MST-X microvortex systems.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Mepsgen social profiles

Digital presence

Mepsgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mepsgen leadership team

Management profile

Number of profiles

Profiles1 record

Mepsgen funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mepsgen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mepsgen

What does Mepsgen do?

MEPSGEN designs, manufactures, and sells microphysiological system (MPS) instruments and microfluidic chips (ProMEPS®, MEPS-X series) alongside automated nanoparticle synthesis systems (NanoCalibur® variants, MST-X microvortex) for pharmaceutical and biotechnology drug discovery, development, and delivery applications. The company also operates a proprietary nanomedicine pipeline (MG-X series) targeting Alzheimer's disease and glioblastoma, and provides contract research services using its platforms.

Is Mepsgen a public or private company?

Mepsgen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mepsgen founded?

Mepsgen was founded in 2019. It employs 11 to 50 people.

Where is Mepsgen based?

Mepsgen is headquartered in Seoul, South Korea, in the Asia region.

How does Mepsgen make money?

Three revenue lines are on record. Research Equipment Sales are the primary driver. The others are research Services and licensing and Co-development.

Who are Mepsgen's main competitors?

Emerging players on record are Fluigent and Organovo. Direct peers are InSphero, TissUse, CN Bio, Dolomite Microfluidics, Emulate and Mimetas. Denali Therapeutics is listed as an others. Precision NanoSystems (Cytiva) is listed as a broad incumbent.

Does Mepsgen have an API?

No public API is recorded for Mepsgen.

What industry is Mepsgen in?

Mepsgen's product category is Drug Discovery Microphysiological Systems. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HDAHALAJ, MEMS Actuators & Micro-Mechanisms (Micromirrors/Microfluidics). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals